In a mechanistic comparison, gi effects refers only to PK/PD processes that can shape digestion-related exposure and concentration–effect transitions. The comparison overview therefore treats sildenafil and vardenafil as two exposure-to-pathway systems rather than as clinical outcome profiles. absorption describes systemic entry from the gastrointestinal tract, while gastric emptying controls the timing with which dissolved drug reaches absorptive intestinal surfaces. distribution then describes movement between plasma and tissue compartments, including concentration gradients relevant to gastrointestinal exposure. metabolism and elimination determine how exposure declines after systemic entry, while half life describes a disposition timescale rather than a complete GI effect window. These PK processes form exposure geometry, including ascending concentration, peak formation, persistence, and decline. The resulting timing can be interpreted alongside pk differences, pd differences, onset speed, and duration length. The term effectiveness is used only as a mechanistic PD construct describing modeled pathway engagement, not real-world effectiveness or a clinical endpoint.
Gastric emptying is a key coupling point between digestion-related physiology and systemic PK because it determines how quickly an orally administered compound progresses from the stomach toward the principal intestinal absorption surfaces. Differences in emptying rate can therefore alter the temporal geometry of systemic input without necessarily changing every downstream disposition process. Once systemic concentrations develop, gastrointestinal tissue exposure can be represented through distribution gradients, compartmental exchange, and local concentration persistence. The metabolism pathway can modify the parent-drug trajectory through metabolic conversion and hepatic handling, while elimination governs subsequent decline. On the PD side, pd differences can be described through PDE5 interaction, changes in cyclic-GMP degradation, and the resulting NO–cGMP signaling environment. Because smooth muscle contains signaling machinery coupled to vascular and other contractile processes, concentration–effect transitions can be represented as changing degrees of pathway engagement. These relationships connect exposure geometry with modeled gi effects, without treating GI effects as clinical outcomes. Differences between sildenafil and vardenafil are therefore framed through the timing and coupling of these mechanistic processes.
GI timing is a composite property of the full PK/PD trajectory rather than a single isolated parameter. Gastric emptying influences the input phase, absorption determines the rising portion of the concentration–time curve, distribution introduces compartmental gradients, metabolism modifies parent-drug persistence, and elimination shapes the declining phase. The resulting exposure geometry can be considered alongside onset speed and duration length because early concentration formation and later persistence represent different regions of one trajectory. The magnitude and timing of PDE5-related pathway engagement can then be mapped to NO–cGMP signaling and smooth-muscle modulation as mechanistic PD transitions. variability, interindividual variability, and clinical variability describe dispersion in these trajectories rather than prescribing any response. In this framework, sildenafil and vardenafil can differ through changes in absorption geometry, distributional coupling, metabolic turnover, clearance, and concentration–effect mapping. The resulting GI-related construct remains descriptive: it explains how exposure and signaling trajectories can intersect with digestion-related timing, without asserting symptom frequency, treatment success, patient outcomes, or real-world comparative effectiveness.
GI PK/PD determinants are mechanistic processes that connect gastrointestinal handling of an oral compound with systemic exposure and downstream concentration–effect behavior. In sildenafil and vardenafil comparison, gi effects is therefore a label for digestion-related PK/PD transitions rather than a clinical endpoint. pk differences can arise from differences in the temporal formation of systemic concentration, while pd differences describe how concentration is translated into molecular pathway engagement. absorption begins with drug availability at intestinal surfaces, but the timing of that availability is coupled to gastric emptying, dissolution, and intestinal transit. distribution then introduces movement between plasma and tissue compartments, producing concentration gradients that can influence local exposure geometry. These processes are linked sequentially: gastric emptying controls input timing, absorption forms systemic exposure, and distribution determines how that exposure is partitioned. The resulting concentration–time trajectory provides the PK substrate for later PD interpretation.
Gastric emptying acts as an upstream timing variable because an orally administered molecule generally cannot contribute to intestinal systemic input until it progresses through the gastric compartment. A slower emptying process can broaden or delay the appearance of material at intestinal absorptive surfaces, whereas a different emptying geometry can shift the timing and slope of systemic input. This does not by itself define the complete exposure profile because absorption rate and extent, distribution, metabolism, and elimination remain separate determinants. In a sildenafil-versus-vardenafil framework, these processes can therefore be represented as linked but distinguishable stages. absorption establishes the ascending exposure phase, while distribution determines compartmental movement after systemic entry. pk differences can consequently be interpreted through altered input, partitioning, or persistence rather than through a single GI parameter. The GI construct remains mechanistic because it describes how digestive handling modifies exposure geometry and timing, without assigning a clinical meaning to any particular concentration–time pattern.
The PD component begins when circulating concentration is translated into target-level pathway engagement. For PDE5 inhibitors, the relevant mechanistic sequence can be represented as PDE5 interaction, altered cGMP degradation, modification of the NO–cGMP signaling environment, and downstream smooth-muscle modulation. pd differences therefore concern concentration–effect coupling rather than clinical response claims. A changing concentration produces a corresponding position along a concentration–effect relationship, while tissue distribution can create temporal gradients between plasma and local compartments. distribution provides the compartmental context for these gradients, and gi effects describes the GI-related portion of the modeled pathway coupling. The resulting PD trajectory can be temporally aligned with the ascending, peak, and declining portions of systemic exposure. This makes gastric emptying relevant indirectly: it can alter when systemic concentrations begin to rise, which shifts when concentration-dependent pathway transitions can occur. The mechanistic distinction is therefore between upstream digestive input geometry and downstream signaling geometry, with no assumption that either represents a clinical outcome.
GI-related PK determinants describe the disposition processes that shape how an oral dose moves from the digestive tract into systemic circulation and subsequently declines. absorption is the first major determinant because the rate and extent of systemic entry establish the ascending portion of the exposure curve. Gastric emptying can modify that input indirectly by controlling the delivery of drug to intestinal absorptive surfaces. distribution then determines how rapidly and extensively drug leaves plasma and enters tissue or other compartments, producing concentration gradients that can affect the temporal relationship between plasma and local exposure. metabolism changes parent-drug exposure through biochemical transformation and contributes to the rate at which circulating concentrations decline. elimination represents the integrated removal processes governing exposure loss from the system. For sildenafil and vardenafil, mechanistic differences can therefore be described as differences in the geometry produced by these linked processes. The resulting curve contains an input phase, distributional movement, persistence, and decline rather than a single GI timing parameter.
Absorption geometry can be separated into rate, extent, and timing. Rate determines the slope of early systemic input, extent influences the amount entering circulation, and timing determines when concentration begins to rise and when peak formation develops. Gastric emptying couples digestive physiology to this geometry by controlling the delivery of orally administered material from the stomach toward intestinal absorption sites. Once systemic entry occurs, distribution determines movement among compartments and can produce different local concentration trajectories from the central plasma trajectory. metabolism then modifies the parent compound through enzymatic transformation, while elimination controls the net loss of drug and metabolites according to their relevant disposition pathways. In a comparison of sildenafil and vardenafil, these dimensions can be treated independently for mechanistic interpretation while remaining coupled in the complete concentration–time model. GI-related timing therefore emerges from the combined geometry of digestive input and systemic disposition rather than from gastric emptying alone.
The relationship between GI exposure and systemic PK is also influenced by the transition from absorption-dominated dynamics to distribution- and elimination-dominated dynamics. During the early phase, changes in gastrointestinal delivery can alter the slope of concentration formation. During the intermediate phase, distribution can redistribute drug between plasma and tissue compartments, changing local concentration gradients. During the later phase, metabolism and elimination increasingly shape the descending exposure trajectory. absorption, distribution, metabolism, and elimination therefore represent distinct components of one coupled PK system. A sildenafil-versus-vardenafil comparison can describe differences in how these components combine without assigning a clinical interpretation to the resulting curve. The key mechanistic output is exposure geometry: the timing, slope, peak formation, persistence, and decline of circulating and compartmental concentrations. That geometry becomes the input to PD modeling, where concentration-dependent pathway engagement is evaluated separately from the underlying disposition processes.
| GI Determinant | PK Basis | Role in Exposure Geometry |
|---|---|---|
| Gastric emptying | Transfer from gastric contents toward intestinal absorption surfaces | Controls the timing and temporal spread of systemic input |
| Absorption rate | Rate of drug movement into systemic circulation | Shapes the ascending slope and early concentration formation |
| Distribution | Movement between plasma and tissue compartments | Creates concentration gradients and alters compartmental persistence |
| Metabolic turnover | Biochemical transformation of parent drug | Contributes to changes in parent-drug concentration over time |
| Elimination | Net removal through metabolic and excretory processes | Shapes the declining phase and exposure persistence |
GI-related PD determinants describe how drug concentration is translated into molecular signaling transitions relevant to smooth-muscle regulation. In the sildenafil and vardenafil comparison, pd differences can be represented through differences in concentration–effect coupling, target engagement, and downstream signaling geometry. PDE5 interaction alters the degradation dynamics of cyclic GMP, which modifies the balance within the NO–cGMP signaling environment. That signaling state can influence smooth-muscle regulatory processes through changes in intracellular second-messenger dynamics. effectiveness is used here only as a mechanistic PD construct describing modeled pathway engagement, not as a clinical outcome. distribution remains relevant because local tissue concentration does not necessarily mirror plasma concentration instantaneously. Compartmental gradients can therefore shift the timing of target-level exposure relative to systemic exposure. elimination subsequently influences how long concentration remains within different regions of the concentration–effect relationship. These mechanisms form a continuous PD trajectory rather than a discrete GI event.
Smooth-muscle modulation is a downstream interpretation of molecular signaling rather than an independent PK parameter. When PDE5 interaction changes cGMP degradation, the resulting NO–cGMP environment can modify signaling processes associated with smooth-muscle contractile state. The temporal pattern of this modulation depends on the concentration reaching the relevant compartment and the relationship between concentration and pathway engagement. distribution can introduce delays or gradients between plasma and tissue concentrations, while elimination determines how the available parent-drug concentration subsequently declines. duration length is therefore interpreted mechanistically as persistence of exposure and pathway engagement over a modeled time window, not as a clinical duration claim. For sildenafil and vardenafil, the comparison can focus on how exposure geometry intersects with the concentration–effect relationship. A rising concentration can move the modeled system toward greater target engagement, while a declining concentration can move it back toward lower engagement. These transitions provide the PD component of GI-related mechanistic interpretation.
The concentration–effect relationship provides the bridge between PK exposure and GI-related PD timing. If systemic concentration changes rapidly, the corresponding target-level concentration may traverse the concentration–effect curve over a different temporal pattern than when exposure rises more gradually. Distribution can modify this relationship by creating compartmental delays, while elimination determines how quickly the trajectory returns toward lower concentration ranges. pd differences can therefore be discussed in terms of PDE5 interaction, NO–cGMP signaling, and smooth-muscle modulation without implying a clinical result. effectiveness remains a mechanistic term for modeled pathway engagement, while gi effects identifies the digestive-context portion of the PK/PD model. The resulting geometry can be viewed as a sequence: systemic exposure rises, tissue concentration develops, pathway engagement changes, signaling transitions occur, and exposure subsequently declines. This sequence explains why GI timing cannot be reduced to absorption alone. It emerges from coupling between input, distribution, molecular signaling, and disposition.
Half-life and clearance describe disposition timescales that become particularly important after the initial absorption phase. half life summarizes the time associated with a proportional decline in concentration under a defined kinetic framework, whereas clearance represents the efficiency of irreversible removal from circulating exposure. elimination therefore governs the declining portion of the concentration–time trajectory, while metabolism can provide a major pathway through which parent-drug exposure is transformed. In a sildenafil-versus-vardenafil comparison, pk differences can be interpreted through differences in these disposition processes without treating half-life as equivalent to a GI effect window. The GI construct depends on the full trajectory, including absorption, distribution, metabolic turnover, and elimination. A longer or shorter disposition timescale changes exposure persistence, but it does not independently determine the timing of gastric emptying or the initial absorption phase. Mechanistically, clearance acts downstream of systemic entry and contributes to how quickly concentrations move through the declining region of the exposure curve.
Clearance can be considered at several mechanistic levels. Metabolic clearance represents removal associated with biochemical transformation, while excretory clearance represents removal through relevant elimination pathways. Total clearance integrates the disposition processes contributing to systemic concentration decline. metabolism therefore affects both the identity of circulating compounds and the rate of parent-drug disappearance, whereas elimination provides the broader framework for net exposure loss. half life emerges from the relationship between clearance and the relevant distribution characteristics rather than acting as an independent GI mechanism. pk differences can consequently alter the persistence of exposure even when the initial gastric input is considered separately. The GI-related interpretation is that later concentration persistence can extend or compress the period over which concentration-dependent PD transitions remain represented in the model. This does not establish a clinical outcome. It describes only how disposition kinetics alter the temporal availability of parent drug for downstream concentration–effect coupling.
The terminal phase of a concentration–time curve can contain information about prolonged disposition, redistribution, and residual elimination processes. For GI-related interpretation, this phase matters because tissue concentrations may decline on a different timescale from the initial plasma rise. distribution can therefore interact with half life to shape persistence in peripheral compartments, while metabolism and elimination continue to determine the direction and rate of exposure decline. A sildenafil-versus-vardenafil comparison can represent these relationships through distinct exposure geometries without reducing them to a single parameter. The transition from absorption to distribution to elimination is continuous, and the resulting concentration trajectory supplies the time-dependent input for PD interpretation. When concentration remains within a modeled concentration–effect region, PDE5 interaction and NO–cGMP signaling can remain part of the mechanistic pathway description. As concentration declines, pathway engagement correspondingly moves through lower regions of the modeled relationship. GI timing is therefore connected to clearance through exposure persistence, not through a direct claim about clinical duration.
| Clearance Component | PK Basis | Interpretation |
|---|---|---|
| Metabolic clearance | Biochemical conversion of parent drug | Contributes to parent-drug concentration decline and exposure persistence |
| Excretory clearance | Removal through relevant excretory pathways | Contributes to net systemic exposure loss |
| Total clearance | Integrated systemic removal capacity | Determines the rate at which circulating exposure is reduced |
| Distribution-linked decline | Redistribution between central and peripheral compartments | Can modify the apparent shape of concentration decline |
| Terminal disposition | Late-phase redistribution and elimination processes | Shapes residual exposure and the later concentration trajectory |
GI-related variability represents dispersion in the PK/PD processes that determine digestive input, systemic exposure, tissue distribution, and concentration–effect transitions. variability can arise when gastric emptying, absorption rate, distribution, metabolic turnover, or elimination differs across modeled trajectories. interindividual variability describes differences between individuals in these mechanistic parameters, while clinical variability can be used descriptively for observed dispersion without converting that dispersion into an outcome claim. The gi effects construct therefore concerns variability in digestion-related PK/PD geometry rather than frequency or severity of a clinical symptom. A change in gastric emptying can shift the timing of intestinal input, while differences in systemic disposition can alter the subsequent rise, peak, persistence, and decline of exposure. These PK differences propagate into PD because concentration determines the position along the PDE5 concentration–effect relationship. Variability can consequently appear as timing spread, exposure spread, compartmental differences, or differences in the modeled transition between concentration and pathway engagement.
Interindividual differences in GI PK can be represented through changes in the timing and magnitude of systemic input. Gastric emptying may alter the temporal delivery of drug to intestinal absorption surfaces, while absorption processes determine the rate and extent of systemic entry. Once exposure forms, distribution creates compartment-specific trajectories, metabolism modifies parent-drug concentrations, and elimination determines subsequent decline. These processes can interact, so a difference in one stage can change the apparent geometry of another stage without implying a separate clinical mechanism. variability therefore describes the spread of PK trajectories, while interindividual variability identifies differences between modeled subjects or populations. clinical variability is treated only as a descriptive category for dispersion and not as evidence of comparative effectiveness or clinical outcome. For sildenafil and vardenafil, mechanistic comparison can thus focus on how differences in input, distribution, metabolism, and elimination propagate into the concentration–effect relationship. The resulting GI timing remains a modeled PK/PD construct.
Timing geometry is particularly useful for separating early input variability from later disposition variability. A shift in gastric emptying primarily affects when drug reaches intestinal absorption surfaces, whereas a change in absorption rate affects the slope of systemic concentration formation. Distribution can introduce delays between plasma and tissue exposure, while metabolism and elimination influence the descending trajectory. The resulting variation can alter when a concentration–effect transition is represented and how long a modeled pathway-engagement state persists. gi effects therefore encompasses the combined geometry rather than a single digestive parameter. variability provides the general framework, interindividual variability describes differences between trajectories, and clinical variability describes observed dispersion without implying a clinical recommendation. In sildenafil and vardenafil comparison, these concepts support a neutral mechanistic interpretation: differences may be represented through altered input, exposure persistence, compartmental coupling, and concentration–effect timing. No particular trajectory is assigned a preferred clinical meaning.
Gastric emptying influences GI-related PK geometry by controlling the timing with which an orally administered compound progresses from the stomach toward intestinal surfaces where systemic absorption can occur. It therefore acts as an upstream input-timing process rather than as a direct measure of systemic exposure. A change in emptying rate can shift the onset of intestinal drug availability, alter the temporal spread of input, and modify the ascending portion of the concentration–time trajectory. The resulting systemic profile still depends on absorption rate and extent, distribution, metabolism, and elimination. In a mechanistic sildenafil-versus-vardenafil comparison, gastric emptying is consequently one component of a coupled PK sequence. It can change when concentration begins to rise without independently determining peak concentration, tissue exposure, half-life, or downstream pathway engagement. GI effects are treated only as a mechanistic description of these linked timing processes, not as a clinical outcome.
GI absorption geometry describes the temporal and quantitative pattern through which an orally administered compound enters systemic circulation from the gastrointestinal tract. Its major dimensions include the timing of intestinal availability, the rate of systemic entry, the extent of absorption, and the resulting slope of the ascending concentration–time curve. Gastric emptying can influence this geometry by controlling delivery from the stomach to intestinal absorptive surfaces. Once intestinal availability develops, dissolution, permeability, transport, and other absorption processes determine how systemic input forms. The resulting trajectory is then modified by distribution, metabolism, and elimination. For sildenafil and vardenafil, GI absorption geometry therefore represents a mechanistic PK dimension rather than a clinical measure. Differences can be described through altered timing, rate, or extent of exposure formation without claiming that one trajectory produces a particular real-world result. The term GI effects remains restricted to this PK/PD framework.
Distribution relates to GI exposure by determining how circulating drug moves between plasma and tissue compartments after systemic entry. Plasma concentration and tissue concentration are not necessarily identical at every moment because compartmental exchange requires time. This can produce concentration gradients and temporal offsets between central and peripheral compartments. For a GI-related PK/PD model, distribution therefore adds another layer to the exposure geometry established by gastric emptying and absorption. A rising plasma concentration may be followed by changing tissue concentrations as equilibration proceeds, while later redistribution can influence the apparent shape of the declining trajectory. These processes are separate from metabolism and elimination, although all contribute to the complete concentration–time profile. In sildenafil and vardenafil comparison, GI distribution is consequently interpreted as a compartmental process affecting local exposure timing. It does not by itself establish a clinical GI outcome or imply a comparative effectiveness conclusion.
Metabolism influences GI-related PK by transforming parent drug and contributing to the rate at which parent-drug exposure changes after systemic entry. Although metabolic processes are not identical to gastric digestion, they become relevant to the later phases of the GI-related exposure trajectory because they modify the concentration available for downstream distribution and concentration–effect coupling. Hepatic metabolic activity can contribute to presystemic handling and systemic clearance, while metabolic turnover after absorption contributes to the decline of circulating parent compound. In a sildenafil-versus-vardenafil model, metabolism can therefore alter exposure persistence and the timing of later concentration transitions. It remains distinct from gastric emptying and intestinal absorption, which primarily shape the input phase. The complete trajectory emerges from coupling these processes with distribution and elimination. GI effects are treated here only as a mechanistic PK/PD construct, so metabolism is discussed in terms of exposure geometry and timing rather than clinical symptom frequency, clinical benefit, or real-world effectiveness.
Elimination influences GI timing by determining how quickly systemic exposure declines after absorption and distribution have established circulating and tissue concentrations. It includes the net processes responsible for removal of drug from the relevant systemic compartments, including metabolic and excretory pathways. A faster or slower elimination trajectory changes the descending portion of the concentration–time curve and therefore changes the period over which concentrations occupy particular regions of a concentration–effect relationship. Elimination does not directly control gastric emptying or intestinal absorption, so it primarily affects later exposure geometry rather than the initial input phase. In a sildenafil-versus-vardenafil comparison, elimination can therefore be represented as a downstream determinant of exposure persistence and timing. Its mechanistic relationship to GI effects is indirect: systemic concentration determines the availability of drug for pathway engagement, while elimination progressively reduces that availability. No clinical outcome is inferred from the resulting timing pattern.
NO–cGMP signaling is represented as a molecular PD pathway through which PDE5 interaction can alter cyclic-GMP degradation and thereby modify the signaling environment associated with smooth-muscle regulation. The relevant sequence can be described as target interaction, altered cGMP turnover, changing intracellular signaling, and downstream modulation of smooth-muscle contractile state. The timing of these transitions depends on the concentration reaching the relevant target compartment and the concentration–effect relationship connecting concentration to pathway engagement. Distribution can create temporal differences between plasma and tissue exposure, while elimination determines how concentration subsequently declines. In a sildenafil-versus-vardenafil comparison, NO–cGMP signaling is therefore a mechanistic PD layer rather than a clinical endpoint. GI effects refers only to how such pathway transitions can be represented in a digestion-related PK/PD model. The framework does not claim a particular symptom, benefit, incidence, or real-world effectiveness for either compound.
Smooth-muscle modulation describes a downstream PD process in which molecular signaling changes alter the regulatory environment controlling smooth-muscle contractile state. For PDE5 inhibitors, this can be represented through PDE5 interaction, reduced cGMP degradation, and modification of the NO–cGMP signaling environment. The resulting signaling state can influence intracellular mechanisms involved in smooth-muscle regulation. The temporal pattern of modulation depends on the concentration–effect relationship and on the distribution of drug into the relevant compartment. Consequently, smooth-muscle modulation is not an isolated event occurring independently of PK. It is coupled to exposure geometry, tissue concentration, target engagement, and subsequent elimination. In a sildenafil-versus-vardenafil comparison, differences are therefore described through pathway coupling and concentration-dependent transitions rather than through clinical outcome statements. The GI context refers to the mechanistic possibility of digestive smooth-muscle pathway involvement, while the analysis remains neutral and descriptive. No claim about symptom occurrence, treatment success, or comparative effectiveness follows from this construct.
Exposure geometry describes the shape and timing of the concentration–time trajectory, including the ascending phase, peak formation, distributional changes, persistence, and decline. GI timing is influenced because the initial trajectory depends partly on gastric emptying and absorption, while later geometry depends increasingly on distribution, metabolism, and elimination. A faster rise can produce earlier traversal of a concentration–effect relationship, whereas a more gradual rise represents a different temporal pathway through the same conceptual relationship. Peak concentration and half-life describe particular properties of exposure but do not independently define the complete GI timing construct. In sildenafil and vardenafil comparison, exposure geometry therefore provides the PK framework for interpreting when concentration-dependent PD transitions can occur. The subsequent NO–cGMP and smooth-muscle pathway changes remain mechanistically linked to target exposure. GI effects is consequently used only to describe these modeled PK/PD timing relationships and does not indicate a clinical outcome or real-world effectiveness.
GI-related variability can arise from differences in gastric emptying, intestinal absorption, distribution, metabolic turnover, elimination, and concentration–effect coupling. Each process can alter a different region of the overall trajectory. Gastric emptying primarily affects the timing of intestinal delivery, absorption influences systemic input, distribution creates compartmental gradients, metabolism modifies parent-drug exposure, and elimination shapes the declining phase. PD variability can then emerge when different exposure trajectories intersect the concentration–effect relationship at different times or concentrations. Interindividual variability describes differences between individuals in these mechanistic parameters, while clinical variability can be used as a descriptive term for observed dispersion without implying a specific outcome. In sildenafil-versus-vardenafil comparison, variability therefore represents spread across PK/PD trajectories rather than a ranking between compounds. GI effects remains a mechanistic label for the digestion-related portion of this model. The framework does not convert variability into clinical advice, recommendations, or effectiveness claims.
Mechanistic GI timing should be interpreted as the temporal relationship among digestive input, systemic exposure, tissue distribution, molecular signaling, and disposition. It is not a single clock time determined by one parameter. Gastric emptying influences when drug becomes available for intestinal absorption, absorption shapes early systemic input, distribution affects tissue concentration gradients, metabolism modifies parent-drug persistence, and elimination determines the later decline. These PK processes establish the concentration trajectory that is then mapped onto PDE5 interaction, NO–cGMP signaling, and smooth-muscle modulation. The resulting PD transitions can occur across different regions of the exposure curve rather than at one discrete moment. In sildenafil and vardenafil comparison, mechanistic timing therefore means describing how these coupled processes form and change exposure geometry. GI effects is used solely as a label for this PK/PD construct. It does not represent a clinical endpoint, a recommendation, a prediction of patient experience, or a statement about real-world effectiveness.